Tim Watkins - 28 Jan 2026 Form 4 Insider Report for Contineum Therapeutics, Inc. (CTNM)

Role
CMO & Head of Development
Signature
/s/ Peter Slover, Attorney-in-Fact
Issuer symbol
CTNM
Transactions as of
28 Jan 2026
Net transactions value
-$34,939
Form type
4
Filing time
30 Jan 2026, 16:52:05 UTC
Previous filing
30 Dec 2025
Next filing
02 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Watkins Tim CMO & Head of Development 3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO /s/ Peter Slover, Attorney-in-Fact 30 Jan 2026 0002065965

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTNM Class A Common Stock Options Exercise $16,250 +3,611 $4.50 3,611 28 Jan 2026 Direct F1
transaction CTNM Class A Common Stock Sale $39,441 -2,800 -78% $14.09 811 28 Jan 2026 Direct F1, F2
transaction CTNM Class A Common Stock Sale $11,747 -811 -100% $14.48 0 28 Jan 2026 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTNM Stock Option (right to buy) Options Exercise $0 -3,611 -1.4% $0.000000 252,778 28 Jan 2026 Class A Common Stock 3,611 $4.50 Direct F1, F4
transaction CTNM Stock Option (right to buy) Award $0 +160,000 $0.000000 160,000 30 Jan 2026 Class A Common Stock 160,000 $14.26 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.44 to $14.39, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.45 to $14.53, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F4 One-half of the option shares vested on October 28, 2025, and the remainder vests in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service.
F5 Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service.